Literature DB >> 29374320

Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.

Maria Ciolina1, Michele Di Martino1, Onorina Bruno2, Romain Pommier2, Valérie Vilgrain2,3,4, Maxime Ronot5,6,7.   

Abstract

AIM: To describe the effect of hepatobiliary-specific MR imaging contrast agent (HBCA) administration on the signal intensity of peritoneal and pleural fluid effusions on T1-weighted MR images.
MATERIALS AND METHODS: From October 2015 to May 2016 139 patients (mean 60±10 years old, 69 % males) with peritoneal or pleural effusions without biliary leakage who underwent HBCA-MRI (Gd-BOPTA or Gd-EOB-DTPA) at 1.5T and 3T were included from two centres. The fluid signal intensity was classified as hypo/iso/hyperintense before/after HBCA administration. The relative signal enhancement (RE) was calculated.
RESULTS: On hepatobiliary phase (HBP), peritoneal fluids appeared hyper/isointense in 88-100 % and pleural effusions in 100 % of the patients following Gd-BOPTA administration. All fluids remained hypointense following Gd-EOB-DTPA. The signal intensity of fluids increased with both HBCA but RE was significantly higher following Gd-BOPTA (p=0.002 to <0.001). RE was correlated with HBP acquisition time-point (r=0.42, p<0.001 and r=0.50, p=0.033 for peritoneal and pleural fluids).
CONCLUSION: The signal intensity of pleural and peritoneal fluids progressively increases following HBCA administration in the absence of biliary leakage. Due to its later hepatobiliary phase, this is more pronounced after Gd-BOPTA injection, leading to fluid hyperintensity that is not observed after Gd-EOB-DTPA injection. KEY POINTS: • Fluids appear hyper/isointense on HBP in most patients after Gd-BOPTA injection. • Fluids remain hypointense on HBP after Gd-EOB-DTPA injection. • RE of fluids increases with time after liver-specific Gd injection. • RE of fluids is higher in patients with chronic liver disease.

Entities:  

Keywords:  Ascites; Bile ducts; Contrast media; Liver; Pleural effusion

Mesh:

Substances:

Year:  2018        PMID: 29374320     DOI: 10.1007/s00330-017-5261-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Opacification of ascitic fluid on delayed contrast computed tomography scans.

Authors:  A M Hammerman; P A Oberle; N Susman
Journal:  Clin Imaging       Date:  1990-08       Impact factor: 1.605

2.  Bile duct leaks after laparoscopic cholecystectomy: value of contrast-enhanced MRCP.

Authors:  M Aduna; J A Larena; D Martín; B Martínez-Guereñu; I Aguirre; E Astigarraga
Journal:  Abdom Imaging       Date:  2005 Jul-Aug

3.  Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver.

Authors:  Antonin Libra; Cristina Fernetti; Vito Lorusso; Massimo Visigalli; Pier Lucio Anelli; Frantisek Staud; Claudio Tiribelli; Lorella Pascolo
Journal:  J Pharmacol Exp Ther       Date:  2006-08-08       Impact factor: 4.030

4.  Gadoxetate disodium-enhanced magnetic resonance cholangiography for the noninvasive detection of an active bile duct leak after laparoscopic cholecystectomy.

Authors:  Daniele Marin; Valentina Bova; Francesco Agnello; Richard Youngblood; Massimo Midiri; Giuseppe Brancatelli
Journal:  J Comput Assist Tomogr       Date:  2010 Mar-Apr       Impact factor: 1.826

5.  Drainage of radiographic contrast media from the abdominal cavity. Experimental studies in rats.

Authors:  I Lindgren; E J Nagy; P Virtama
Journal:  Acta Radiol Diagn (Stockh)       Date:  1968-11

6.  Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?

Authors:  Mustafa R Bashir; Rajan T Gupta; Matthew S Davenport; Brian C Allen; Tracy A Jaffe; Lisa M Ho; Daniel T Boll; Elmar M Merkle
Journal:  J Magn Reson Imaging       Date:  2012-09-25       Impact factor: 4.813

Review 7.  Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.

Authors:  Matthew D F McInnes; Rebecca M Hibbert; João R Inácio; Nicola Schieda
Journal:  Radiology       Date:  2015-05-26       Impact factor: 11.105

8.  Visualization of the biliary tract using gadobenate dimeglumine: preliminary findings.

Authors:  Fatma Bilge Ergen; Deniz Akata; Basar Sarikaya; Ulku Kerimoglu; Mutlu Hayran; Okan Akhan; Hero K Hussain
Journal:  J Comput Assist Tomogr       Date:  2008 Jan-Feb       Impact factor: 1.826

9.  The ultrastructural basis of capillary permeability studied with peroxidase as a tracer.

Authors:  M J Karnovsky
Journal:  J Cell Biol       Date:  1967-10       Impact factor: 10.539

10.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

View more
  3 in total

1.  Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Authors:  Matteo Bonatti; Riccardo Valletta; Giulia A Zamboni; Fabio Lombardo; Maria Senoner; Mariachiara Simioni; Guenther Schifferle; Giampietro Bonatti
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

Review 2.  MR Imaging of the Perihepatic Space.

Authors:  Angèle Bonnin; Carole Durot; Manel Djelouah; Anthony Dohan; Lionel Arrivé; Pascal Rousset; Christine Hoeffel
Journal:  Korean J Radiol       Date:  2020-11-19       Impact factor: 3.500

3.  Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B.

Authors:  Carlos Moctezuma-Velázquez; Sara Lewis; Karen Lee; Salvatore Amodeo; Josep M Llovet; Myron Schwartz; Juan G Abraldes; Augusto Villanueva
Journal:  JHEP Rep       Date:  2021-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.